Clinical trial NCT04114578: Exploratory Observational Prospective Study in Neonatal and Pediatric Congenital Diaphragmatic Hernia
Official title: ECHO-CDH - Exploratory Observational Prospective Study in Neonatal and Pediatric Congenital Diaphragmatic Hernia
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Congenital Diaphragmatic Hernia
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Sponsor class: OTHER
First posted: 2019-10-03
Enrollment: 80
Sex: ALL
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The control groups will be recruited in the normal nursery, in the NICU (term infants with antenatal suspicion of coarctation, which is ruled-out postnatally) or in clinics with conditions non-related to lungs or heart (such as: Inguinal hernia, Dermatology, Orthopedic and Benign Chest Pain clinics), as described in our previous published studies .

Brief summary: CDH is associated with lung hypoplasia, pulmonary hypertension, and left ventricular hypoplasia.

Use of new STE techniques (heart ultrasound) showed that CDH newborns have decreased LV size and function, potentially explaining the non-response to iNO, and that these cardiac findings were associated with poor outcomes. Our hypothesis: CDH newborns persist to have some degree of LV hypoplasia in the pediatric and adolescent life and pulmonary pressures remain increased during growth. Patients with decreased cardiac performance by STE and/or with PH have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile

Detailed description: The principal investigator hypothesize that CDH newborns have disturbed cardiac performance and increased pulmonary pressures during neonatal life and at different pediatric ages. The principal investigator also postulate that those with decreased cardiac performance by STE and/or with PH have higher concomitant neonatal or pediatric morbidities and altered neurodevelopmental profile, that CDH patients have some remaining degree of LV hypoplasia at pediatric/adolescent age and that novel echocardiography techniques will detect anomalies not uncovered by conventional imaging.

This study is a prospective study. Cohorts will be simultaneously recruited at different neonatal and pediatric ages to create various age groups of the CDH populations.

Groups will be synchronized with the current follow-up programs to ease feasibility.

Patient Population will be CDH patients admitted to the NICU at the MCH or followed in the clinic. Patients will be recruited during hospitalization or at the different age groups corresponding to their regular CDH follow-up.

Echocardiography will be targeted to acquire: RV and LV function by STE, 3D derived RV/LV volumes and performance , conventional systolic/diastolic RV and LV function parameters (such as: ejection fraction by Simpson's Biplane, tricuspid annular plane systolic excursion and tissue Doppler velocities), cardiac outputs and pulmonary pressure estimates. For patient's safety, responsible clinician will be alerted when a clinically significant anomaly is detected on the research echocardiography. Same echocardiography protocol will be applied to controls.

Associated to echocardiography data, The principal investigator will complete a chart review to extract important neonatal/pediatric demographic and clinical data. Variables extracted, among others, will include perinatal details (mode of delivery, maternal conditions, APGAR scores), sex, birth weight, clinical course and major morbidities. Bayley Scales of Infant and Toddler Development - Third Edition, a standardized evaluation for motor, cognitive and language abilities, is done on all patients with CDH at 18 months PMA at the MCH. When available for age groups beyond 18 months of age, these scores will be recorded. As well, assessment tools describing functional and developmental status will be filled with parents (or legal guardian) and/or pre-adolescents/adolescents. These tools will be the: Ages \& Stages Questionnaires 3 (a parent report of developmental skills for ages of 2 to 60 months , the Clinical Adaptive Test /Clinical Linguistic Auditory Milestone Scale (CAT/CLAMS), which has a high correlation with the Bayley Scales of Infant Development and is a neurodevelopmental assessment tool of infants and toddlers) and the Pediatric Quality of Life Inventory Survey (a pre-adolescent and adolescent report on quality of life and functional status).

Patients with CDH will be compared to controls (1:1) recruited contemporaneously. Clinics targeted for control groups include the dermatology, orthopedic, trauma follow-up and neurology clinic for benign seizures episodes.

Eligibility criteria: Inclusion:

* CDH patients admitted to the MCH-NICU
* CDH followed at the MCH CDH clinic

Exclusion:

* Prematurity (\< 36 weeks)
* Diagnosis at \> 7 days of life
* Bilateral CDH
* Congenital cardiac defect (excluding a patent ductus arteriosus (PDA), atrial septal defect (ASD) or ventricular septal defect (VSD)) and/or other major anomaly/genetic syndrome.

Primary outcomes:
measure: Assessment of cardiac function
timeFrame: Within 24 hours of life
measure: Assessment of cardiac function
timeFrame: Between day 3 to 5 of life
measure: Assessment of cardiac function
timeFrame: Between 2 to 3 weeks of life
measure: Assessment of cardiac function
timeFrame: age of 4 and/or 9 months
measure: Assessment of cardiac function
timeFrame: 3, 5 and/or 8 years
measure: Assessment of cardiac function
timeFrame: 11, 14 and/or 17 years
Secondary outcomes:
measure: Prevalence of pulmonary hypertension
timeFrame: Within 24 hours of life
measure: Prevalence of pulmonary hypertension
timeFrame: Between day 3 to 5 of life
measure: Prevalence of pulmonary hypertension
timeFrame: Between 2 to 3 weeks of life
measure: Prevalence of pulmonary hypertension
timeFrame: age of 4 and/or 9 months
measure: Prevalence of pulmonary hypertension
timeFrame: 3, 5 and/or 8 years
measure: Prevalence of pulmonary hypertension
timeFrame: 11, 14 and/or 17 years
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Mcgill University Health Centre
state: Quebec
Study officials:
References: